Surufatinib: First Approval

Surufatinib (Sulanda(R)), an oral angio-immuno kinase inhibitor that selectively targets VEGFR 1, 2, and 3, FGFR1 and CSF-1R, is being developed by HUTCHMED for the treatment of solid tumours, including neuroendocrine tumours (NETs). On 30 December 2020, surufatinib received its first approval in China for the treatment of late-stage, well-differentiated, extrapancreatic NET. Surufatinib is in preregistration in China for pancreatic NET and in the USA for pancreatic and extrapancreatic NET; phase II development is underway for other solid tumours, including thyroid cancer, biliary tract carcinoma and soft tissue sarcoma. This article summarizes the milestones in the development of surufatinib leading to this first approval for extrapancreatic NET.

Automated summary

Surufatinib is an oral angio-immuno kinase inhibitor that has received approval in China for the treatment of extrapancreatic neuroendocrine tumors. It is also being studied for pancreatic NET and other solid tumors in the USA. The drug selectively targets VEGFR, FGFR, and CSF-1R.